tetano
Editor, Senior Moderator
Bioprocess Biosyst Eng
. 2022 Jan 15.
doi: 10.1007/s00449-021-02674-9. Online ahead of print.
Automatic system for high-throughput and high-sensitivity diagnosis of SARS-CoV-2
Jun Lu[SUP] 1 2 [/SUP], Weihua Fan[SUP] 2 [/SUP], Zihui Huang[SUP] 1 [/SUP], Ke Fan[SUP] 1 2 [/SUP], Jianhua Dong[SUP] 1 2 [/SUP], Jisheng Qin[SUP] 1 2 [/SUP], Jianzhong Luo[SUP] 1 2 [/SUP], Zhizhong Zhang[SUP] 1 2 [/SUP], Guodong Sun[SUP] 1 [/SUP], Chaohui Duan[SUP] 3 [/SUP], Kunyi Pan[SUP] 3 [/SUP], Wenshen Gu[SUP] 3 [/SUP], Xiao Zhang[SUP] 4 5 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had severe consequences for health and the global economy. To control the transmission, there is an urgent demand for early diagnosis and treatment in the general population. In the present study, an automatic system for SARS-CoV-2 diagnosis is designed and built to deliver high specification, high sensitivity, and high throughput with minimal workforce involvement. The system, set up with cross-priming amplification (CPA) rather than conventional reverse transcription-polymerase chain reaction (RT-PCR), was evaluated using more than 1000 real-world samples for direct comparison. This fully automated robotic system performed SARS-CoV-2 nucleic acid-based diagnosis with 192 samples in under 180 min at 100 copies per reaction in a "specimen in data out" manner. This throughput translates to a daily screening capacity of 800-1000 in an assembly-line manner with limited workforce involvement. The sensitivity of this device could be further improved using a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based assay, which opens the door to mixed samples, potentially include SARS-CoV-2 variants screening in extensively scaled testing for fighting COVID-19.
Keywords: High throughput; Robotic system; SARS-CoV-2 diagnosis.
. 2022 Jan 15.
doi: 10.1007/s00449-021-02674-9. Online ahead of print.
Automatic system for high-throughput and high-sensitivity diagnosis of SARS-CoV-2
Jun Lu[SUP] 1 2 [/SUP], Weihua Fan[SUP] 2 [/SUP], Zihui Huang[SUP] 1 [/SUP], Ke Fan[SUP] 1 2 [/SUP], Jianhua Dong[SUP] 1 2 [/SUP], Jisheng Qin[SUP] 1 2 [/SUP], Jianzhong Luo[SUP] 1 2 [/SUP], Zhizhong Zhang[SUP] 1 2 [/SUP], Guodong Sun[SUP] 1 [/SUP], Chaohui Duan[SUP] 3 [/SUP], Kunyi Pan[SUP] 3 [/SUP], Wenshen Gu[SUP] 3 [/SUP], Xiao Zhang[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35031864
- DOI: 10.1007/s00449-021-02674-9
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had severe consequences for health and the global economy. To control the transmission, there is an urgent demand for early diagnosis and treatment in the general population. In the present study, an automatic system for SARS-CoV-2 diagnosis is designed and built to deliver high specification, high sensitivity, and high throughput with minimal workforce involvement. The system, set up with cross-priming amplification (CPA) rather than conventional reverse transcription-polymerase chain reaction (RT-PCR), was evaluated using more than 1000 real-world samples for direct comparison. This fully automated robotic system performed SARS-CoV-2 nucleic acid-based diagnosis with 192 samples in under 180 min at 100 copies per reaction in a "specimen in data out" manner. This throughput translates to a daily screening capacity of 800-1000 in an assembly-line manner with limited workforce involvement. The sensitivity of this device could be further improved using a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based assay, which opens the door to mixed samples, potentially include SARS-CoV-2 variants screening in extensively scaled testing for fighting COVID-19.
Keywords: High throughput; Robotic system; SARS-CoV-2 diagnosis.